Immutopics, Inc. was acquired by Diagnostic Hybrids, Inc., a wholly owned subsidiary of Quidel Corporation, on March 18, 2016. Quidel is excited to have Immutopics join the Quidel family and portfolio of products and believes the combination of the Immutopics portfolio with Quidel's MicroVueTM products will enhance our ability to serve the bone health research community. Please see About Us for additional information.


About Us


Immutopics, Inc. was acquired by Diagnostic Hybrids, Inc. (DHI), a wholly owned subsidiary of Quidel Corporation, on March 18, 2016. Quidel is excited to have Immutopics join the Quidel family and portfolio of products and believes the combination of the Immutopics portfolio with Quidel’s MicroVue™ products will enhance our ability to serve the bone health research community.

In connection with the acquisition and integration process, please contact Quidel’s Customer Service team by calling 800.874.1517 or at customerservice@quidel.com. To assist Quidel’s Customer Service team, please indicate that you are an Immutopics customer. Effective June 1, 2016, billing, invoicing and collections have transitioned to Quidel. Payment for all transactions after May 31, 2016 should be made to Quidel.

Quidel is in the process of contacting existing Immutopics customers to facilitate a smooth transition of customers’ needs. Please contact us as follows if you have any questions:

Quidel Corporation
2005 East State Street, Suite 100
Athens, OH 45701 USA
Tel: 800.874.1517 (in the U.S.)/858.552.1100 (outside the U.S.)
E-mail: customerservice@quidel.com